Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy, Safety and Tolerability of Nangibotide in Patients with Septic Shock
2018-004827-36Phase 2Completed
- Sponsor
- Inotrem
- Start
- Jun 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nangibotide in septic shock (3 arms), sponsored by Inotrem. Primary endpoints: Change in total SOFA score from baseline to day 5 (high sTREM-1 subgroup) and Change in total SOFA score from baseline to day 5 (overall population). Started Jun 2019; status: completed.
02
Drugs
nangibotide
03
Conditions
septic shock
Beyond the preview
Go deeper on 2018-004827-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004827-36.